Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry

Semaglutide just got a lot more accessible in Canada. Hims, a telehealth company, is now offering Apotex’s generic version of semaglutide after the original patent from Novo Nordisk expired. This move cracks open the market for researchers who want to work with a major metabolic peptide—without the brand-name price tag.

Why does this matter? The original semaglutide molecule has been at the center of metabolic and weight management research for years. Patent protection kept options limited and pricing high. Now, with generic versions like Apotex’s on the scene, researchers can source semaglutide more easily and affordably. That’s a big win for anyone exploring GLP-1 receptor agonists and their applications.

Key points:

For anyone in the peptide research space, this is a signal to watch the Canadian market. When generics hit, sourcing costs drop and study possibilities expand. The ripple effect might even reach other markets if regulatory environments shift.

For those looking to source or compare semaglutide options, it’s worth checking vendor availability and pricing. You can browse our semaglutide research peptide page for details, or find reliable suppliers in our vendor directory.

Patent expiries don’t happen every day. This one just made semaglutide research easier for everyone north of the border.